Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| C5A-C51H9 | Cynomolgus | Cynomolgus Complement C5a Protein, His Tag |  |
|
|
| C5A-H51H9 | Human | Human Complement C5a Protein, His Tag |  |
|
|
| C5A-H525a | Human | Human Complement C5a Protein, Fc Tag (MALS verified) |  |
|
|
| C5A-C5118 | Cynomolgus | Cynomolgus Complement C5a Protein, Tag Free |  |
|
|
| C5A-M51H4 | Mouse | Mouse Complement C5a Protein, His Tag |  |
|
|
| C5A-H5116 | Human | Human Complement C5a Protein, Tag Free |  |
|
|
Immobilized Human Complement C5a, His Tag (Cat. No. C5A-H51H9) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Human C5a Human Antibody, Human IgG1 with a linear range of 0.1-4 ng/ml (QC tested).
The purity of Human Complement C5a, Fc Tag (Cat. No. C5A-H525a) is more than 90% and the molecular weight of this protein is around 80-90 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Vilobelimab | IFX-1; CaCP-29 | Approved | Inflarx Nv | Gohibic | EU | Respiratory Distress Syndrome, Adult | Inflarx Nv | 2025-01-13 | Granulomatosis with Polyangiitis; Drug-Related Side Effects and Adverse Reactions; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Shock, Septic; Microscopic Polyangiitis; Pyoderma Gangrenosum; Coronavirus Disease 2019 (COVID-19); Sepsis; Respiratory Distress Syndrome, Adult; Hidradenitis Suppurativa; Systemic Inflammatory Response Syndrome | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| BDB-001 | BDB-1; BDB-001; BDB001; BDB 001 | Phase 2 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coronavirus Disease 2019 (COVID-19); Hidradenitis Suppurativa | Details |
| STSA-1002 | STSA-1002; STSA1002 | Phase 2 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult | Details |
This web search service is supported by Google Inc.
A-Z
